Wharton's Jelly: Umbilical Cord Matrix Definition — 50 to 200 Billion EVs Per Vial

Wharton's Jelly is the gelatinous connective tissue matrix surrounding the blood vessels of the umbilical cord, composed primarily of collagen, hyaluronic acid, proteoglycans, and a dense population of mesenchymal stromal cells and extracellular vesicles, used in regenerative medicine as a biological scaffold with an EV payload of 50 to 200 billion particles per vial.

What Wharton's Jelly Is

Wharton's Jelly was first described by Thomas Wharton in 1656, who identified the protective gel-like substance surrounding the umbilical cord vessels. Biochemically, it is an extracellular matrix composed of collagen types I, III, and IV, hyaluronic acid, fibronectin, laminin, and proteoglycans, with embedded mesenchymal stromal cells.

In regenerative medicine, Wharton's Jelly Matrix products deliver two distinct therapeutic components: a structural scaffold that supports tissue architecture and provides a substrate for cellular repair, and a biological signaling component in the form of 50 to 200 billion extracellular vesicles per vial carrying micro-RNA, growth factors, and anti-inflammatory proteins.

This combination, structure plus signal, makes Wharton's Jelly Matrix distinct from pure exosome or pure stem cell products.

How Wharton's Jelly Works in Tissue Repair

The structural components of Wharton's Jelly provide a temporary scaffold that integrates with the extracellular matrix of the treatment site. Collagen and hyaluronic acid support joint lubrication, tissue hydration, and chondrocyte activity in cartilaginous applications. Fibronectin and laminin support cell adhesion and migration.

The EV payload delivers the signaling complement: micro-RNA modulating gene expression, anti-inflammatory proteins suppressing cytokine activity, and growth factors supporting collagen synthesis and angiogenesis.

The dual-component mechanism is particularly relevant for joint applications (knee OA, hip OA) where both the structural matrix support and the biological repair signal are therapeutically useful.

How Rebuild Regen Uses Wharton's Jelly Matrix

Wharton's Jelly Matrix at Rebuild Regen Medical Clinic at 3320 N Federal Hwy #101, Lighthouse Point, FL is available as a DayZero™ product from ZEO ScientifiX. It is used as a joint injection for cartilage-related conditions and as a connective tissue support option for patients who want both a scaffold and a biological signal in a single product.

All Wharton's Jelly Matrix protocols at Rebuild Regen involve consultation with Elizabeth Celestin, APRN, FNP-C and protocol review by Dr. Cedric Emden Davis II, MD.

Is Wharton's Jelly Matrix the Right Option for Your Situation?

Wharton's Jelly Matrix is appropriate for patients with joint conditions involving cartilage degeneration, ligamentous laxity, or connective tissue involvement where both structural support and biological signaling are desired. It is an alternative or complement to pure stem cell or exosome products depending on the clinical picture.

Risks and Limitations of Wharton's Jelly Matrix

Wharton's Jelly Matrix products are allogeneic (donor source). They are not FDA-approved as drugs. Sourcing certification (AABB, cGMP, COA) is essential for safety and quality verification. DayZero™ Wharton's Jelly Matrix meets all 5 certification standards Rebuild Regen requires.